Transcode Historical Income Statement

RNAZ Stock

USD 0.34 0.04 9.71%

Historical analysis of Transcode Therapeutics income statement accounts such as Depreciation And Amortization of 304.6 K, Selling General Administrative of 7.5 B, Total Revenue of 0.0 or Other Operating Expenses of 20.4 M can show how well Transcode Therapeutics performed in making a profits. Evaluating Transcode Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Transcode Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Transcode Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Transcode Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Transcode Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

About Transcode Income Statement Analysis

Transcode Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Transcode Therapeutics shareholders. The income statement also shows Transcode investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Transcode Therapeutics Income Statement Chart

At this time, Transcode Therapeutics' Net Interest Income is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 7.5 B in 2024, whereas Interest Expense is likely to drop slightly above 48.1 K in 2024.

Net Income Applicable To Common Shares Tax Provision Selling General Administrative Research Development

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Most accounts from Transcode Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Transcode Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Transcode Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.At this time, Transcode Therapeutics' Net Interest Income is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 7.5 B in 2024, whereas Interest Expense is likely to drop slightly above 48.1 K in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	42.5K	98.6K	516.7K	304.6K
Interest Income	664.0	20.4K	14.8K	7.9K

Depreciation And Amortization Interest Income

Transcode Therapeutics income statement Correlations

	Ebit	Net Interest Income	Interest Income	Depreciation And Amortization	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Cost Of Revenue	Selling And Marketing Expenses
Ebit		-0.78	-0.91	-0.47	-0.78	-1.0	1.0	1.0	-0.99	1.0	-1.0	1.0	-0.73	0.93	-0.5	0.83	-0.82	-0.75
Net Interest Income	-0.78		0.72	-0.16	0.6	0.79	-0.79	-0.76	0.79	-0.79	0.79	-0.76	0.93	-0.72	0.4	-0.64	0.64	0.57
Interest Income	-0.91	0.72		0.36	0.53	0.89	-0.92	-0.9	0.88	-0.92	0.89	-0.91	0.76	-0.97	0.75	-0.61	0.6	0.57
Depreciation And Amortization	-0.47	-0.16	0.36		0.53	0.46	-0.45	-0.5	0.47	-0.44	0.46	-0.49	-0.13	-0.34	-0.01	-0.54	0.53	0.57
Selling General Administrative	-0.78	0.6	0.53	0.53		0.81	-0.77	-0.79	0.84	-0.77	0.81	-0.77	0.59	-0.51	-0.12	-0.99	1.0	0.95
Other Operating Expenses	-1.0	0.79	0.89	0.46	0.81		-1.0	-1.0	1.0	-1.0	1.0	-1.0	0.75	-0.91	0.46	-0.86	0.86	0.77
Operating Income	1.0	-0.79	-0.92	-0.45	-0.77	-1.0		1.0	-0.99	1.0	-1.0	1.0	-0.75	0.93	-0.51	0.83	-0.82	-0.75
Net Income From Continuing Ops	1.0	-0.76	-0.9	-0.5	-0.79	-1.0	1.0		-0.99	1.0	-1.0	1.0	-0.71	0.92	-0.47	0.84	-0.84	-0.76
Research Development	-0.99	0.79	0.88	0.47	0.84	1.0	-0.99	-0.99		-0.99	1.0	-0.99	0.76	-0.9	0.42	-0.88	0.88	0.79
Ebitda	1.0	-0.79	-0.92	-0.44	-0.77	-1.0	1.0	1.0	-0.99		-1.0	1.0	-0.75	0.94	-0.51	0.82	-0.82	-0.74
Total Operating Expenses	-1.0	0.79	0.89	0.46	0.81	1.0	-1.0	-1.0	1.0	-1.0		-1.0	0.75	-0.91	0.46	-0.86	0.86	0.77
Income Before Tax	1.0	-0.76	-0.91	-0.49	-0.77	-1.0	1.0	1.0	-0.99	1.0	-1.0		-0.71	0.93	-0.5	0.82	-0.82	-0.75
Total Other Income Expense Net	-0.73	0.93	0.76	-0.13	0.59	0.75	-0.75	-0.71	0.76	-0.75	0.75	-0.71		-0.72	0.47	-0.64	0.63	0.56
Net Income	0.93	-0.72	-0.97	-0.34	-0.51	-0.91	0.93	0.92	-0.9	0.94	-0.91	0.93	-0.72		-0.78	0.59	-0.58	-0.49
Income Tax Expense	-0.5	0.4	0.75	-0.01	-0.12	0.46	-0.51	-0.47	0.42	-0.51	0.46	-0.5	0.47	-0.78		0.03	-0.03	-0.11
Gross Profit	0.83	-0.64	-0.61	-0.54	-0.99	-0.86	0.83	0.84	-0.88	0.82	-0.86	0.82	-0.64	0.59	0.03		-1.0	-0.96
Cost Of Revenue	-0.82	0.64	0.6	0.53	1.0	0.86	-0.82	-0.84	0.88	-0.82	0.86	-0.82	0.63	-0.58	-0.03	-1.0		0.94
Selling And Marketing Expenses	-0.75	0.57	0.57	0.57	0.95	0.77	-0.75	-0.76	0.79	-0.74	0.77	-0.75	0.56	-0.49	-0.11	-0.96	0.94

Click cells to compare fundamentals

Transcode Therapeutics Account Relationship Matchups

Transcode Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	157.0K	394.6K	95.1K	17.6M	50.6K	48.1K
Ebit	(456.9K)	(1.5M)	(6.2M)	(17.6M)	(18.5M)	(17.6M)
Net Income Applicable To Common Shares	(607.2K)	(2.3M)	(6.8M)	(17.6M)	(15.8M)	(15.0M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Transcode Historical Income Statement

About Transcode Income Statement Analysis

Transcode Therapeutics Income Statement Chart

Net Income Applicable To Common Shares

Tax Provision

Transcode Therapeutics income statement Correlations

Transcode Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Transcode Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Transcode Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Operating Income	+ 1.0	Ebit
Net Income From Continuing Ops	+ 1.0	Ebit
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit
Cost Of Revenue	+ 1.0	Selling General Administrative
Research Development	+ 1.0	Other Operating Expenses

Cost Of Revenue	- 1.0	Gross Profit
Income Before Tax	- 1.0	Total Operating Expenses
Total Operating Expenses	- 1.0	Ebitda
Total Operating Expenses	- 1.0	Net Income From Continuing Ops
Total Operating Expenses	- 1.0	Operating Income
Income Before Tax	- 1.0	Other Operating Expenses